Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-cf6xr Total loading time: 0 Render date: 2025-04-24T15:35:20.966Z Has data issue: false hasContentIssue false

Chapter 49 - Stem Cell Transplantation: Clinical Potential in Treating Fetal Genetic Disease

from Fetal Stem Cell Transplantation

Published online by Cambridge University Press:  21 October 2019

By
Åsa Ekblad  and
Cecilia Götherström
Edited by
Mark D. Kilby ,
Anthony Johnson  and
Dick Oepkes
Mark D. Kilby
Affiliation:
University of Birmingham
Anthony Johnson
Affiliation:
University of Texas Medical School at Houston
Dick Oepkes
Affiliation:
Leids Universitair Medisch Centrum
Get access

Summary

Inherited severe genetic diseases are rare but devastating disorders associated with vast morbidity and mortality. Currently there is no cure for many of these diseases, but merely pharmacological therapies replacing the missing gene product or inhibiting the progressing pathology of the disease. Stem cell transplantation has the possibility to restore the defect permanently and hematopoietic stem cell transplantation (HSCT) is today used postnatally to cure sickle-cell disease, severe combined immunodeficiency (SCID), and other immune disorders [1, 2]. However, the pathology is progressing with sustained morbidity during fetal life and the disease may already be manifested at birth.

Type
Chapter
Information
Fetal Therapy
Scientific Basis and Critical Appraisal of Clinical Benefits
 , pp. 512 - 519
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Kassim, AA, Sharma, D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017; 10: 259–66.Google Scholar
Raje, N, Dinakar, C. Overview of immunodeficiency disorders. Immunol Allergy Clin North Am. 2015; 35: 599–623.CrossRefGoogle ScholarPubMed
Sagar, R, Walther-Jallow, L, David, AL, Götherström, C, Westgren, M. Fetal mesenchymal stromal cells: an opportunity for prenatal cellular therapy. Curr Stem Cell Rep. 2018; 4: 61–8.Google Scholar
Squillaro, T, Peluso, G, Galderisi, U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016; 25: 829–48.CrossRefGoogle ScholarPubMed
Nijagal, A, Flake, AW, MacKenzie, TC. In utero hematopoietic cell transplantation for the treatment of congenital anomalies. Clin Perinatol. 2012; 39: 301–10.Google Scholar
Tiblad, E, Westgren, M. Fetal stem-cell transplantation. Best Pract Res Clin Obstet Gynaecol. 2008; 22 : 189–201.Google Scholar
Touraine, JL, Raudrant, D, Royo, C, Rebaud, A, Roncarolo, MG, Souillet, G, et al. In-utero transplantation of stem cells in bare lymphocyte syndrome. Lancet. 1989; 1: 1382.Google Scholar
Vrecenak, JD, Flake, AW. In utero hematopoietic cell transplantation –recent progress and the potential for clinical application. Cytotherapy. 2013; 15: 525–35.Google Scholar
Flake, AW, Zanjani, ED. In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers. Blood. 1999; 94: 2179–91.Google Scholar
Westgren, M, Ringdén, O, Eik-Nes, S, Ek, S, Anvret, M, Brubakk, AM, et al. Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies. Transplantation. 1996; 61: 1176–9.CrossRefGoogle ScholarPubMed
Loewendorf, AI, Csete, M, Flake, A. Immunological considerations in in utero hematopoetic stem cell transplantation (IUHCT). Front Pharmacol. 2014; 5: 282.Google Scholar
Perez, B, Vilageliu, L, Grinberg, D, Desviat, LR. Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery. Nucleic Acid Ther. 2014; 24: 48–56.Google Scholar
Baris, HN, Cohen, IJ, Mistry, PK. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev. 2014; 12 (Suppl. 1): 72–81.Google ScholarPubMed
Charrow, J, Scott, CR. Long-term treatment outcomes in Gaucher disease. Am J Hematol. 2015; 90 (Suppl. 1): S19–24.Google Scholar
Orvisky, E, Sidransky, E, McKinney, CE, Lamarca, ME, Samimi, R, Krasnewich, D, et al. Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr Res. 2000; 48: 233–7.CrossRefGoogle ScholarPubMed
Müller, I, Kustermann-Kuhn, B, Holzwarth, C, Isensee, G, Vaegler, M, Harzer, K, et al.. In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients.. Exp Hematol. 2006; 34: 1413–19.Google Scholar
Weiss, K, Gonzalez, A, Lopez, G, Pedoeim, L, Groden, C, Sidransky, E. The clinical management of Type 2 Gaucher disease. Mol Genet Metab. 2015; 114: 110–22.CrossRefGoogle ScholarPubMed
Meregalli, M, Farini, A, Belicchi, M, Parolini, D, Cassinelli, L, Razini, P, et al. Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS J. 2013; 280: 4251–62.Google Scholar
Flanigan, KM. Duchenne and Becker muscular dystrophies. Neurol Clin. 2014; 32: 671–88, viii.Google Scholar
Mendell, JR, Rodino-Klapac, LR, Sahenk, Z, Roush, K, Bird, L, Lowes, LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013; 74: 637–47.CrossRefGoogle ScholarPubMed
Aartsma-Rus, A, Goemans, N. A Sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe. Nucleic Acid Ther. 2019; 29: 13–15.CrossRefGoogle Scholar
Falzarano, MS, Scotton, C, Passarelli, C, Ferlini, A. Duchenne muscular dystrophy: from diagnosis to Therapy. Molecules. 2015; 20: 18168–84.CrossRefGoogle ScholarPubMed
Cordova, G, Negroni, E, Cabello-Verrugio, C, Mouly, V, Trollet, C. Combined therapies for duchenne muscular dystrophy to optimize treatment efficacy. Front Genet. 2018; 9: 114.CrossRefGoogle ScholarPubMed
Chan, J, Waddington, SN, O’Donoghue, K, Kurata, H, Guillot, PV, Götherström, C, et al. Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. Stem Cells. 2007; 25: 875–84.Google Scholar
de Carvalho, SC, Hindi, SM, Kumar, A, Marques, MJ. Effects of omega-3 on matrix metalloproteinase-9, myoblast transplantation and satellite cell activation in dystrophin-deficient muscle fibers. Cell Tissue Res. 2017; 369: 591–602.CrossRefGoogle ScholarPubMed
Aminzadeh, MA, Rogers, RG, Fournier, M, Tobin, RE, Guan, X, Childers, MK, et al. Exosome-mediated benefits of cell therapy in mouse and human models of duchenne muscular dystrophy. Stem Cell Reports. 2018; 10: 942–55.Google Scholar
Silva, MC, Magalhaes, TA, Meira, ZM, Rassi, CH, Andrade, AC, Gutierrez, PS, et al. Myocardial fibrosis progression in duchenne and becker muscular dystrophy: a randomized clinical trial. JAMA Cardiol. 2017; 2: 190–9.Google Scholar
Marini, JC, Forlino, A, Bachinger, HP, Bishop, NJ, Byers, PH, Paepe, A, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017; 3: 17052.Google Scholar
Folkestad, L, Hald, JD, Canudas-Romo, V, Gram, J, Hermann, AP, Langdahl, B, et al. Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res. 2016; 31: 2159–66.CrossRefGoogle ScholarPubMed
Hald, JD, Evangelou, E, Langdahl, BL, Ralston, SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015; 30: 929–33.CrossRefGoogle ScholarPubMed
Dwan, K, Phillipi, CA, Steiner, RD, Basel, D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014; 7: CD005088.Google Scholar
Chan, JK, Götherström, C. Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta. Front Pharmacol. 2014; 5: 223.CrossRefGoogle ScholarPubMed
Horwitz, EM, Prockop, DJ, Gordon, PL, Koo, WW, Fitzpatrick, LA, Neel, MD, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001; 97: 1227–31.Google Scholar
Horwitz, EM, Gordon, PL, Koo, WK, Marx, JC, Neel, MD, McNall, RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002; 99: 8932–7.Google Scholar
Le Blanc, K, Götherström, C, Ringden, O, Hassan, M, McMahon, R, Horwitz, E, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005; 79: 1607–14.Google Scholar
Götherström, C, Westgren, M, Shaw, SW, Astrom, E, Biswas, A, Byers, PH, et al. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med. 2014; 3: 255–64.Google Scholar
Götherström, C, Hermerén, G, Johansson, M, Sahlin, N-E, Westgren, M. Stem cells and fetal therapy: is it a reality? Obstet Gynecol Reprod Med. 2017; 27: 166–7.Google Scholar
MacKenzie, TC, David, AL, Flake, AW, Almeida-Porada, G. Consensus statement from the first international conference for in utero stem cell transplantation and gene therapy. Front Pharmacol. 2015; 6: 15.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×